Many other preclinical studies on hepatocellular carcinoma [114], prostate cancer [118], and breast cancer showed that either depletion of CCR2 or breaking the CCL2-CCR2 interaction has an impact on inhibition of TAMs recruitment and tumor regression or inhibition of metastasis [119]. The gene discussed is CCR2; the disease is Familial prostate cancer.